Fraxinellone reduced the increase in CUGBP1 and α-SMA to approximately normal levels, which supports the use of CUGBP1 as a new specific biomarker of liver fibrosis (Fig. 7). The gene discussed is ACTA1; the disease is Hepatic fibrosis.